Publications

Mirvetuximab Soravtansine

Meeting

Title

ESMO 2020

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: final results from a Phase 1b study in patients (pts) with ovarian cancer

ASCO 2020

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum Agnostic Ovarian Cancer

ASCO 2020

GOG 3045/ENGOT OV55/MIRASOL: A Randomized, Open Label, Phase 3 Study of Mirvetuximab Soravtansine versus Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Alpha Receptor Expression

ESMO 2019

FORWARD I (GOG 3011): A Phase III Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate, Versus Chemotherapy in Patients with Platinum-resistant Ovarian Cancer

ESMO 2019

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Carboplatin and Bevacizumab: Initial results from a Phase 1b Study in Patients (pts) with Ovarian Cancer

ASCO 2019

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Bevacizumab in Patients (pts) with Platinum-resistant Ovarian Cancer: Final Analyses from the FORWARD II Study

ESMO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), with Pembrolizumab in Platinum-Resistant Ovarian Cancer (PROC): Initial Results of an Expansion Cohort from FORWARD II, a Phase Ib Study

ASCO 2018

Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer: Maturing Safety and Activity Profile from the FORWARD II Phase 1b Study

SGO 2018

Initial Safety and Activity Findings from a Phase IB Escalation Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC) in Combination with Pembrolizumab in Platinum-Resistant Epithelial Ovarian Cancer Patients

SGO 2017

Characterization of Folate Receptor Alpha (FRα) Expression in Archival Tumor and Biopsy Samples in a Phase I Study of Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), in Relapsed Epithelial Ovarian Cancer Patients

ASCO 2017

Safety Findings from FORWARD II: a Phase IB Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), Mirvetuximab Soravtansine (IMGN853), in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin (PLD), or Pembrolizumab in Patients with Ovarian Cancer

ASCO 2017

Mirvetuximab Soravtansine (IMGN853), a Floate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC), in Platinum-Resistant Epithelial Ovarian Cancer (EOC) Patients: Activity and Safety Analyses in Phase I Pooled Expansion Cohorts

SITC 2016

Treatment of Tumor Cells with Mirvetuximab Soravtansine, a FRα-Targeting Antibody Drug Conjugate (ADC), Activates Monocytes Through Fc-FcyR Interaction and Immunogenic Cell Death

ASCO 2016

IMGN853 (Mirvetuximab Soravtansine), a Folate Receptor Alpha (FRα)-Targeting Antibody Drug Conjugate (ADC): Single Agent Activity in Platinum-Resistant Ovarian Cancer (EOC) Patients

AACR 2015

Preclinical Evaluation of Mirvetuximab Soravtansine (IMGN853) Combination Therapy in Ovarian Cancer Xenograft Models

AACR 2015

Development and Application of an Immunohistochemistry-Based Clinical Assay for Evaluating Folate Receptor Alpha (FRα) Expression in the Clinical Setting

IMGN632

Meeting

Title

ASCO 2020

A Phase 1/2 Study of IMGN632, a Novel CD123 Targeting Antibody Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123 Positive Hematologic Malignancies

ASCO 2020

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123 Positive Acute Myeloid Leukemia

ASH2019

Encouraging Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

ASH2019

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

ASH2019

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

ASH2019

A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, and Other CD123- Positive Hematologic Malignancies

EHA 2019

The Combination of IMGN632, a CD123-Targeting ADC, with Venetoclax Enhances Anti-Leukemic Activity In vitro and Prolongs Survival In vivo in Pre-Clinical Models of Human AML

ASH 2018

A Phase 1, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

EHA 2016

IMGN632: A Novel Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Potent DNA-Alkylator is Highly Active in Preclinical Models of AML with Poor Prognosis

ASH 2016

Oral Presentation: A CD123-Targeting Antibody Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow

ASH 2016

IMGN632: An Antibody Drug Conjugate (ADC) of a CD123-Targeting Antibody with a Novel DNA-Alkylating Payload is Highly Active and Prolongs Survival in AML Xenograft Models

IMGN151

Meeting

Title

AACR 2020

IMGN151: A Next Generation Folate Receptor Alpha Targeting Antibody-Drug Conjugate Active Against Tumors with Low, Medium, and High Receptor Expression

IMGC936

Meeting

Title

AACR 2019

IMGC936, a First-in-Class ADAM9-Targeting Antibody-Drug Conjugate, Demonstrates Promising Anti-Tumor Activity

Early Pipeline

Meeting

Title

AACR 2019 Posters